A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07743671 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Hemorrhagic Telangiectasia

Interventions

DRUG: Engasertib
DRUG: Placebo

Sponsor

Vaderis Therapeutics AG